Epidermal melanoma prognostic factors: a link to paracrine transforming growth factor-β signalling

Gyorgy Paragh^{1

2}

Affiliations

Comment

Gyorgy Paragh. Br J Dermatol. 2022 Apr.

. 2022 Apr;186(4):606-607.

doi: 10.1111/bjd.20981. Epub 2022 Mar 2.

Gyorgy Paragh^{1

2}

¹ Department of Dermatology.
² Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

No abstract available

Comment on

Melanoma secretion of transforming growth factor-β2 leads to loss of epidermal AMBRA1 threatening epidermal integrity and facilitating tumour ulceration.
Cosgarea I, McConnell AT, Ewen T, Tang D, Hill DS, Anagnostou M, Elias M, Ellis RA, Murray A, Spender LC, Giglio P, Gagliardi M, Greenwood A, Piacentini M, Inman GJ, Fimia GM, Corazzari M, Armstrong JL, Lovat PE. Cosgarea I, et al. Br J Dermatol. 2022 Apr;186(4):694-704. doi: 10.1111/bjd.20889. Epub 2021 Dec 27. Br J Dermatol. 2022. PMID: 34773645 Free PMC article.

1. Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M et al., eds. SEER Cancer Statistics Review 1975-2018. Bethesda, MD: National Cancer Institute, 2021. Available at: https://seer.cancer.gov/csr/1975_2018/ (last accessed 4 January 2022).
1. Almashali M, Ellis R, Paragh G. Melanoma epidemiology, staging and prognostic factors. In: Practical Manual for Dermatologic and Surgical Melanoma Management (Lee DJ, Faries MB, eds), 1st edn. Cham, Switzerland: Springer, 2020; 61-81.
1. Zhou C, Louwman M, Wakkee M et al. Primary melanoma characteristics of metastatic disease: a nationwide cancer registry study. Cancers (Basel) 2021; 13:4431.
1. Eggermont AMM, Suciu S, Testori A et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012; 48:218-25.
1. Braun-Falco M, Friedrichson E, Ring J. Subepidermal cleft formation as a diagnostic marker for cutaneous malignant melanoma. Hum Pathol 2005; 36:412-15.